Does a large published testing history at SSA imply lot consistency?

This is my second independent submission on material from the same supplier.

I understand the observation; what I do not understand is the mechanism behind it.

I have read the two review articles that come up first and both assert this without a citation to a primary source.

So what is the mechanism, and how well established is it?

If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Specifically, published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

Specifically, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 22 Mar 2025 by marta_okonkwo — clarified the distinction between purity and content

Stated carefully, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.